home / stock / srpt / srpt articles

SRPT Articles, Sarepta Therapeutics Inc. - From 05/30/24

Stock Information
Company Name: Sarepta Therapeutics Inc.
Stock Symbol: SRPT
Market: NASDAQ
Website: sarepta.com
Menu
SRPT SRPT Quote SRPT Short SRPT News SRPT Articles SRPT Message Board
Get SRPT Alerts

News, Short Squeeze, Breakout and More Instantly...
Why Sarepta Therapeutics Stock Is Rising Today | Benzinga

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap...
With FDA Decision Date Approaching, Analyst Downgrades Sarepta On Balanced Risk And Reward | Benzinga

RBC Capital Markets has downgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) as it weighs recent investor feedback, company commentary, and public s...

Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months | Benzinga

RBC Capital Markets has downgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) as it weighs recent investor feedback, company commentary, and ...

Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir | Benzinga

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Enbridge Inc. (NYSE:ENB). “I trust that management team,R...
Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday | Benzinga

With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street...

This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO | Benzinga

RBC Capital Markets upgraded REGENXBIO Inc (NASDAQ:RGNX), a company focused on developing gene therapies. Recently, REGENXBIO reported ad...

Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices | Benzinga

In a significant trend, pharmaceutical companies in the U.S. introduced new drugs last year at prices 35% higher than in 2022, notably attributed t...
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards? | Benzinga

BeiGene (NASDAQ: BGNE) is expected to report its fourth-quarter 2023 results soon. BeiGene currently markets three internally discovered oncology p...

FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight | Benzinga

Friday, the FDA accepted and filed Sarepta Therapeutics Inc’s (NASDAQ:SRPT) efficacy supplement to the Biologics License Application (BLA) ...

Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session | Benzinga

Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quart...
Previous 10 Next 10